Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lieberman

Showing results (821-830 of 1,142) with videos related to

Pageof 115
Sort By:
Biological Psychiatry|October 8, 2015
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled TrialJeffrey A Lieberman, Robert E Davis, Christoph U Correll, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 2, 2017
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in SchizophreniaRagy R Girgis, Adam Ciarleglio, Tse Choo, et al.
Digestive Diseases and Sciences|August 20, 2003
Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortiumDeepak V Gopal, David A Lieberman, Nathan Magaret, et al.
The Journal of Clinical Psychiatry|September 28, 2010
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophreniaDonald E Addington, Somaia Mohamed, Robert A Rosenheck, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 14, 2005
Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacyJeffery A Lieberman, Joel Greenhouse, Robert M Hamer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 8, 2010
Association study of the GSK-3B gene with tardive dyskinesia in European CaucasiansRenan P Souza, Gary Remington, Nabilah I Chowdhury, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|May 29, 2009
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trialHuei-Ting Tsai, Stanley N Caroff, Del D Miller, et al.
Neuroepidemiology|May 21, 1998
Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementiaJ P Hubble, J H Kurth, S L Glatt, et al.
Cancer Causes & Control : CCC|August 13, 2016
A prognostic model for advanced colorectal neoplasia recurrenceLin Liu, Karen Messer, John A Baron, et al.
Journal of Psychopharmacology (Oxford, England)|February 16, 2018
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placeboJacob S Ballon, Utpal B Pajvani, Laurel Es Mayer, et al.
Pageof 115

Showing results (821-830 of 1,142) with videos related to

Sort By:
Pageof 115
Biological Psychiatry|October 8, 2015
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled TrialJeffrey A Lieberman, Robert E Davis, Christoph U Correll, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 2, 2017
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in SchizophreniaRagy R Girgis, Adam Ciarleglio, Tse Choo, et al.
Digestive Diseases and Sciences|August 20, 2003
Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortiumDeepak V Gopal, David A Lieberman, Nathan Magaret, et al.
The Journal of Clinical Psychiatry|September 28, 2010
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophreniaDonald E Addington, Somaia Mohamed, Robert A Rosenheck, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 14, 2005
Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacyJeffery A Lieberman, Joel Greenhouse, Robert M Hamer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 8, 2010
Association study of the GSK-3B gene with tardive dyskinesia in European CaucasiansRenan P Souza, Gary Remington, Nabilah I Chowdhury, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|May 29, 2009
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trialHuei-Ting Tsai, Stanley N Caroff, Del D Miller, et al.
Neuroepidemiology|May 21, 1998
Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementiaJ P Hubble, J H Kurth, S L Glatt, et al.
Cancer Causes & Control : CCC|August 13, 2016
A prognostic model for advanced colorectal neoplasia recurrenceLin Liu, Karen Messer, John A Baron, et al.
Journal of Psychopharmacology (Oxford, England)|February 16, 2018
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placeboJacob S Ballon, Utpal B Pajvani, Laurel Es Mayer, et al.
Pageof 115